Bausch & Lomb Incorporated introduced TotalVisc Viscoelastic System and the StableVisc cohesive ophthalmic viscosurgical device (OVD) with special benefits intended to guarantee the best surgical results for patients. StableVisc aids in maintaining room in the anterior chamber of the eye, whereas TotalVisc Viscoelastic System, guards the ocular tissue during surgery.
Novartis AG acquired Kedalion Therapeutics and its AcuStream technology that might help with accurate dosage and administration of several topical ophthalmic drugs to the eye, and to meet unmet patient needs in front-of-eye disorders.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3999
Published Date: Aug 04, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising cases of ocular diseases such as glaucoma, corneal opacification, and others are the major factors driving the market growth.
The market size of ophthalmoscope is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Eli Lilly and Company, Bausch & Lomb Incorporated, Sun Pharmaceutical Industries Ltd., Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc, and others.
The diabetes segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.